Who is sponsoring NCT05140759?

NCT05140759 is sponsored by Paragate Medical LTD.

What drugs are being tested in NCT05140759?

Interventions in NCT05140759: automated continual water removal system.

What condition does NCT05140759 study?

NCT05140759 studies Heart Failure.

Is NCT05140759 still recruiting?

NCT05140759 is currently terminated. Last updated 19 January 2024.

Last reviewed 2024-01-19 · How we verify

NCT05140759: ACWR-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Automated Continual Water Removal System in Patients With Advanced Diuretic Resistant Heart Failure

Terminated NA Last updated 19 January 2024

What this trial tests

NA trial testing automated continual water removal system in Heart Failure in 3 participants. Terminated before completion.

Timeline

24 February 2022

Primary endpoint
17 January 2024

17 January 2024

Quick facts

Lead sponsor	Paragate Medical LTD
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	24 February 2022
Primary completion	17 January 2024
Estimated completion	17 January 2024
Sites	3 locations across Georgia, Israel, Poland

Drugs / interventions tested

automated continual water removal system

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Paragate Medical LTD

Who can join

21 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the functionality and tolerability of an automated continual water removal system in up to 8 patients with HF and diuretic resistance. intervention: Implanted absorption chamber, connected to an external pump. Follow up: 3 months post activation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Paragate Medical LTD trials

Trials by the same sponsor.

NCT06689553 — Percutaneously Delivered Automated Continual Fluid Removal System in Patients With Advanced Diuretic-Resistant Heart Fai · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05140759 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paragate Medical LTD
Last refreshed: 19 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05140759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing